As the biopharma industry innovates new drug modalities like biologics, ADCs, and gene therapies, EHS leaders are facing increasing challenges in managing safety and sustainability. The 2nd EHS&S for Biopharma Summit West offered a unique opportunity to explore how pharma and biotech organizations are adapting their EHS strategies for 2025 to proactively mitigate risks, protect workers, and minimize environmental impact across R&D and manufacturing.

Across two days, 21+ EHS leaders shared real-world case studies and innovative approaches to biosafety, waste management and risk assessment. Attendees explored the use of AI and automation for smarter decision-making, safety considerations for novel containment strategies, and cutting-edge training technologies such as AVR.

With expert speakers from Gilead, Takeda, AbbVie, Lonza, Illumina, and more, this summit provided an unmatched platform to collaborate with EHS professionals across the life sciences industry. Don’t miss the opportunity to gain practical insights, benchmark your strategies, and help shape the future of safety and sustainability in pharma and biotech in 2026.